|Day Low/High||29.32 / 29.92|
|52 Wk Low/High||25.55 / 35.60|
Shares lost more than 16% in London trading
The Nasdaq tumbles and the S&P 500 slides. The Dow rises slightly.
But not all stocks were helping to push the market higher.
Losses at several major index constituents sank markets Thursday.
These stocks were moving big before the market opened.
Alexion Pharmaceuticals, United Therapeutics and Gilead Sciences were among the biotech stock movers in premarket trading on July 27.
Facebook blows everyone away, again.
AstraZeneca today announced that the Phase III FLAURA trial showed a statistically-significant and clinically-meaningful progression-free survival (PFS) benefit with TAGRISSO ® (osimertinib) compared to current...
AstraZeneca calls MYSTIC results "disappointing".
Global equity rally takes a breather.
Wall Street's first glimpse at the second quarter.
In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.
The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.
AstraZeneca shares rose after the group said its CEO would host an earnings call later this month following speculation he was to take up a similar role Teva Pharmaceuticals.
Rumors swirled that Pascal Soriot would leave for rival Teva Pharmaceuticals.
CEO Pascal Soriot may be on his way to Israel's Teva Pharmaceuticals ahead of key drug trial information release.
Neither company has confirmed Pascal Soriot's move.
European benchmarks held gains much of Thursday.
AstraZeneca shares dropped in the first hours of trading Thursday after it was reported that Teva Pharmaceuticals was courting its CEO.
AstraZeneca CEO Pascal Sorio will reportedly take over at Teva.
The FDA has placed a clinical hold on three combination studies of Merck's Keytruda in multiple myeloma.
Celgene acquired the rights to BeiGene's PD-1 checkpoint inhibitor, propelling the biotech giant forward in immuno-oncology research.
Several firms hiked price targets on Portola into the $70s this week.